Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

P2RX3 antagonist BAY 1817080

An orally bioavailable antagonist of the purinergic receptor P2X ligand-gated ion channel 3 (P2RX3), which may potentially be used to suppress pain and chronic cough. Upon oral administration, P2RX3 antagonist BAY1817080 selectively binds to and inhibits P2RX3 expressed on sensory nerve fibers. This may inhibit P2RX3-mediated afferent nerve fiber signaling including respiratory tract afferent nerve fiber signaling, and result in the suppression of pain and chronic cough. P2RX3 plays an important role in the cough reflex. It is also a natural mediator of pain and neurogenic inflammation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:P2X ligand-gated ion channel 3 receptor antagonist BAY 1817080
P2X purinoceptor 3 antagonist BAY 1817080
P2X3 receptor antagonist BAY 1817080
Code name:BAY 1817080
BAY-1817080
BAY1817080
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search